BioCentury's websites will be down for upgrades starting at 9 p.m. PDT on Monday, August 26. We expect the downtime to last no more than 6 hours, and we apologize for any inconvenience.

12:00 AM
 | 
Mar 19, 2007
 |  BioCentury  |  Strategy

Schering-Plough's protein shake

Schering-Plough Corp.'s decision to acquire Organon BioSciences N.V. for

11 billion ($14.4 billion) in cash looks to have three broad consequences for the pharma company. It will move SGP into the class of mid/large-cap pharmaceutical companies with large-scale protein production capabilities, bulk up the company's late-stage pipeline, and widen its offerings in marketed products for primary care to include women's health and CNS.

Organon, the pharmaceuticals and animal health subsidiary of Akzo Nobel N.V. (Euronext:AKZ; AKZOY, Arnhem, the...

Read the full 396 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >